Management patients myelodysplastic syndromes myelodysplastic syndromes group clonal hematologic neoplasms course ineffective hematopoiesis leukemic transformation Therapeutic results past patients supportive measures transfusions erythrocytes administration antibiotics transfusions platelets active bleeding episodes supportive measures quality life patients myelodysplastic syndromes Vitamin supplementation folate vitamin pyridoxine Differentiation agents cis-retinoic acid benefit limited number patients Androgens useful danazol attenuated androgen effective subset patients presence cell-bound platelet antibodies Low-dose cytarabine differentiating activity vitro low rate complete remission substantial toxicity Antileukemic therapy useful young patients progressive disease Several hematopoietic growth factors clinical trials use combination conjunction chemotherapy new horizons patients improvements prevention treatment graft-versus-host disease allogeneic transplantation viable option patients years age severe cytopenias 